Susquehanna Fundamental Investments LLC Takes Position in Vir Biotechnology, Inc. (NASDAQ:VIR)

Susquehanna Fundamental Investments LLC purchased a new position in shares of Vir Biotechnology, Inc. (NASDAQ:VIR) in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 15,200 shares of the company’s stock, valued at approximately $135,000.

A number of other hedge funds have also recently added to or reduced their stakes in VIR. Vanguard Group Inc. boosted its position in shares of Vir Biotechnology by 0.6% during the 1st quarter. Vanguard Group Inc. now owns 12,375,355 shares of the company’s stock worth $125,362,000 after purchasing an additional 78,216 shares in the last quarter. Millennium Management LLC lifted its stake in shares of Vir Biotechnology by 94.6% in the second quarter. Millennium Management LLC now owns 1,248,131 shares of the company’s stock valued at $11,108,000 after purchasing an additional 606,804 shares during the period. Bank of New York Mellon Corp boosted its holdings in Vir Biotechnology by 0.8% during the second quarter. Bank of New York Mellon Corp now owns 813,288 shares of the company’s stock worth $7,238,000 after buying an additional 6,359 shares in the last quarter. Dimensional Fund Advisors LP grew its position in Vir Biotechnology by 10.1% during the second quarter. Dimensional Fund Advisors LP now owns 637,486 shares of the company’s stock worth $5,673,000 after buying an additional 58,360 shares during the period. Finally, Empowered Funds LLC increased its holdings in Vir Biotechnology by 8.2% in the first quarter. Empowered Funds LLC now owns 458,044 shares of the company’s stock valued at $4,640,000 after buying an additional 34,640 shares in the last quarter. Institutional investors and hedge funds own 65.32% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on the company. HC Wainwright reissued a “buy” rating and set a $110.00 price target on shares of Vir Biotechnology in a research note on Tuesday, August 20th. Barclays upped their target price on Vir Biotechnology from $27.00 to $28.00 and gave the company an “overweight” rating in a report on Friday, August 2nd. Two investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $36.80.

Vir Biotechnology Stock Performance

VIR stock opened at $7.74 on Friday. The stock’s 50 day moving average price is $8.27 and its 200 day moving average price is $9.15. The firm has a market cap of $1.06 billion, a P/E ratio of -1.93 and a beta of 0.46. Vir Biotechnology, Inc. has a 1 year low of $7.12 and a 1 year high of $13.09.

Vir Biotechnology (NASDAQ:VIR) last issued its quarterly earnings data on Thursday, August 1st. The company reported ($1.02) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.89) by ($0.13). The company had revenue of $3.08 million during the quarter, compared to analysts’ expectations of $7.53 million. Vir Biotechnology had a negative net margin of 612.40% and a negative return on equity of 30.93%. The firm’s revenue was down 19.0% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($1.45) earnings per share. On average, research analysts predict that Vir Biotechnology, Inc. will post -3.26 earnings per share for the current year.

Insider Buying and Selling at Vir Biotechnology

In other news, Director Janet Napolitano sold 12,190 shares of Vir Biotechnology stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $7.80, for a total transaction of $95,082.00. Following the completion of the sale, the director now directly owns 11,616 shares in the company, valued at $90,604.80. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 15.60% of the stock is owned by insiders.

About Vir Biotechnology

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company’s preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).